SNY Archives

Illustrated CareDx, Regeneron and Eupraxia representatives stand under spotlights with a DNA helix, laboratory flask and syringe, surrounded by digital medical displays and an applauding audience.

CareDx, Regeneron and Eupraxia Put Precision Medicine in the Spotlight -( $CDNA $EPRX $REGN $SNY )

by John F. Heerdink, Jr. October 31, 2026 323Views 0Likes

AlloSure Kidney Data Excites, Dupixent Sales Surge and POTENTIAL Competitor, EP-104GI, Nears December EoE Catalyst Biotechnology’s most persuasive growth stories are moving beyond laboratory promise and into financial statements, clinical evidence and approaching trial milestones. CareDx (NASDAQ: CDNA) reported third-quarter revenue growth…

Vintage comic-style illustration of three bulls pulling a loaded wagon through sunny farmland, with “EPRX” and “Trio of Bulls” above.

Eupraxia: Three Bullish Analyst Reports Put EP-104GI’s EoE Opportunity in Focus Post Tezspire Results -( $AMGN $APGE $AZN $EPRX $REGN $SNY $TAK )

by John F. Heerdink, Jr. October 12, 2026 714Views 0Likes

Wall Street Price targets of $16, $17 and $18 seem to underscore the potential for a long-acting treatment as December clinical data approach Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) has received a timely vote of confidence from three research firms, with newly…

Biotech professionals collaborate in a modern laboratory with molecular models, digital research displays and blue and green upward arrows symbolizing growth.

Moderna and Novavax Rally: ‘Cancer Vaccine’ Stocks Get a Shot of Investor Confidence -( $IBB $MRK $MRNA $NVAX $SNY $XBI )

by John F. Heerdink, Jr. October 10, 2026 708Views 0Likes

Clinical progress, a proposed U.S. research initiative and vaccine licensing economics strengthen the bull case. Biotechnology investors are finding fresh reasons to look beyond the pandemic trade. Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX) and Merck (NYSE: MRK) rallied on October 9 as…

Promotional graphic for a Tribe Public CEO dinner event featuring Eupraxia Pharmaceuticals (NASDAQ: EPRX), James Helliwell, M.D., and the company’s 52-week EP-104GI clinical update for eosinophilic esophagitis. The image illustrates localized treatment at week zero, durable symptom control through week 52, and a stylized upward EPRX market graphic.

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

by John F. Heerdink, Jr. September 30, 2026 503Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the…

Eupraxia Pharmaceuticals: A Precision Bet on Making Food Enjoyable Again – Meet CEO At The Tribe Event – Friday, August. 21-( $EPRX $REGN $SNY $TAK )

by John F. Heerdink, Jr. August 17, 2026 342Views 0Likes

For patients with eosinophilic esophagitis, eating can become an exercise in calculated risk rather than a simple pleasure. For Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX), that burden represents both an urgent medical problem and a potentially compelling opportunity to prove that…

Tag: SNY

CareDx, Regeneron and Eupraxia Put Precision Medicine in the Spotlight -( $CDNA $EPRX $REGN $SNY )

Eupraxia: Three Bullish Analyst Reports Put EP-104GI’s EoE Opportunity in Focus Post Tezspire Results -( $AMGN $APGE $AZN $EPRX $REGN $SNY $TAK )

Moderna and Novavax Rally: ‘Cancer Vaccine’ Stocks Get a Shot of Investor Confidence -( $IBB $MRK $MRNA $NVAX $SNY $XBI )

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

Eupraxia Pharmaceuticals: A Precision Bet on Making Food Enjoyable Again – Meet CEO At The Tribe Event – Friday, August. 21-( $EPRX $REGN $SNY $TAK )

Your Guide To Staying Informed In The Markets